Cereno Team

Born 1977. Jonas Faijerson Säljö has a research background in the stroke area with wide-ranging experience in the commercialization of medical innovations. Faijerson Säljö has significant expertise in intellectual property and business development experience from a large number of companies in the life science area. He is currently employed as Senior IP Business Consultant and CEO of Synergon AB. Jonas Faijerson Säljö holds a Ph.D. in Neurobiology and is a licensed pharmacist from the University of Gothenburg.

Shareholding: 1,107,904 B shares and 135,440 A shares

Born 1973. Fredrik Frick has extensive experience in research and development and 17 years of combined experience from working at AstraZeneca with early- to late-stage drug development including preclinical target identification, clinical drug discovery, clinical study management and operations and global project management of late-stage projects. Fredrik Frick holds a Ph.D. in Medical Physiology/Endocrinology from the University of Gothenburg.

Shareholding: 300,000 warrants of series 2023/2026

Born 1972. Prof. Michael Holinstat is an Associate Professor in Pharmacology and leads the translational programs in drug development in Hemostasis and Thrombosis in the Department of Pharmacology at the University of Michigan. Prof. Holinstat has built a "state of the art" laboratory to investigate the effects of different pharmacological principles on platelets and coagulation both in vitro and in vivo. Prof. Holinstat is primarily employed as an associate professor at the Department of Pharmacology, Internal Medicine (Division of Cardiovascular Medicine), and Vascular Surgery at University of Michigan Medical School. Prof. Holinstat holds a Ph.D. in Pharmacology from the University of Illinois, Chicago, and completed postdoctoral training at Vanderbilt University in Nashville.

Born 1988. Megha Ranjan has nearly a decade of experience supporting small to large-sized global life sciences companies in defining their strategies using comprehensive market insights, intelligence, and valuations. She has previously gained experience from roles in commercial and scientific teams at large pharmaceutical companies including BD&L valuations, real-world evidence analysis, go-to-market strategies, medical affairs and medical information. Megha Ranjan holds a B.Sc. in Dental Surgery and an MBA in Healthcare Management from IIHMR University, India.

Shareholding: 25,000 warrants

Born 1986. Tatiane Abreu Dall’Agnol is a medical doctor with nearly a decade of clinical experience. She has previously also worked as a life science consultant advising biotech companies on drug development strategy and analysis; and gained experience in business development and competitive intelligence at Pieris Pharmaceuticals. Tatiane has a medical degree from the Universidade Positivo, Curitiba, PR, Brazil, and an M.Sc. in Business Creation and Entrepreneurship in Biomedicine from the University of Gothenburg, Sweden.

Shareholding: 200,000 warrants

J. Donald (Don) de Bethizy, PhD has more than 30 years of experience in managing and financing life science-related technologies and has played a key role in building and advising several life sciences companies. Don de Bethizy advised the CEO and board of NDA Group AB one of the world’s leading private biotechnology regulatory consulting firms until its sale to SSI Strategy in 2023. In 2017, Don facilitated the management buyout of Albumedix Ltd from Novozymes A/S and the subsequent sale of Albumedix Ltd to Sartorius for 415 MGBP in late 2022. He is currently President of White City Consulting ApS (Denmark), a Director at Lophora ApS (Denmark) and Proterris Inc (USA), as well as Vice Chair of the board of argenx NV a global commercial immunology company headquartered in Gent, Belgium with 2023 sales of 1.2 BUSD of its first drug Vyvgart in the rare autoimmune disease myasthenia gravis. In 2014, in his role as Chief Executive Officer of the Danish biotech Santaris Pharma A/S, he led the sale of the company to Roche for 450 MUSD. He co-founded Targacept, Inc. and served as its President and Chief Executive Officer for 15 years. Don de Bethizy led Targacept’s private and US Nasdaq public financings totaling approximately 330 MUSD, including the Company’s Initial Public Offering (IPO) in April 2006. Don de Bethizy holds a B.S. in Biology from the University of Maryland and an M.S. and PhD in Toxicology from Utah State University.